The deck is the slide set used for Pfizer's third quarter 2026 earnings teleconference on November 3, 2026. It opens with a title slide and an investor relations introduction, then a forward-looking statements and non-GAAP disclaimer, followed by opening remarks from the chairman and CEO. The middle sections cover 2026 strategic priorities, progress on value from key transactions, R&D milestones, post-2028 growth investment and AI across the business. A financial review by the CFO follows, with quarterly revenue and non-GAAP highlights, a revenue growth chart, raised 2026 guidance and capital allocation. The scientific update that comes next walks through pipeline assets such as elranatamab, atirmociclib, tivunatamig, tilrekimig and a next-generation pneumococcal vaccine, each with trial data. The deck closes with pre-Q&A remarks, a summary slide, a Q&A placeholder, a pipeline progress table and footnotes defining non-GAAP terms. Slides carry headline-style titles, data callouts and a consistent blue palette, and the text-heavy disclaimer slides sit at the front. Slides 6, 11 and 14 are good examples of big-number callouts, and slide 24 pairs a clinical chart with a short safety panel.
Slides worth studying
- Slide 6: Three equal columns with one large figure each and a short caption make the three transaction results readable at a glance.
- Slide 14: Guidance is shown as large range figures with the prior range in smaller text beneath, so the revision is visible without a table.
- Slide 20: A cross-trial survival chart is paired with a bold hazard ratio callout, which puts the headline result first.
- Slide 24: Efficacy and safety are split into two clearly labelled panels, letting the audience compare the two claims side by side.
Details
- Company: Pfizer
- Year: 2026
- Type: Investor presentation
- Industry: Pharmaceuticals
- Pages: 32
Review score: 7 out of 10, Effective
Presentation quality, judged with the SlideDeck Co review heuristic. Ask, evidence and idea merit are not rated here.
The deck has a clear spine (priorities on slide 5, financial review, then science, then summary on slide 28) and a consistent blue identity with action titles and big-number callouts that read well (slides 6, 11, 14). Weaknesses are consequential: slide 3 is a wall of tiny text, and the scientific slides (19, 21, 22, 23, 26, 30) are very dense with small type and heavy footnotes, so the audience can follow the headline but not the detail on a call. The 4-item priorities slide (5) and the Q&A slide (29) add little, and the pipeline table on slide 30 is hard to scan.
Worth keeping: Keep the consistent blue system, headline-style titles and the big-number callout layouts on slides 6, 11 and 14, plus the clean chart with a takeaway bar on slide 20.
Most useful repair: Cut slide 3 and the footnote pages 31-32 to a readable size or move them to a handout, and enlarge or split the dense science slides (22, 26, 30) so one message leads each page.
What would change the score: I would reduce the number of chart panels and tiny labels per science slide and give slide 9 and slide 26 a clearer visual hierarchy.
Confidence medium. 32 of 32 pages inspected on contact sheets, 4 at readable size. Reviewed 2026-11-10. Model-assisted review (claude-sonnet-5-5).
Full text of the slides (32 slides)
Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.
Slide 1
Third Quarter 2026
Earnings Teleconference
November 3, 2026
1
Visuals: Full-bleed abstract illustration of interlocking ribbon bands, covering the whole slide behind all text. A light blue (#009CFF) band enters from the top edge, curves across the upper right and ends at the right edge. A second light blue band forms a half-loop in the middle right, and a dark blue (#0000CC) band sweeps from the left-middle edge of the ribbon down and across to the bottom right. A dark blue (#0000CC) segment sits at the middle right beside a white gap. The ribbon is cropped by the right and bottom edges. A Pfizer logo (blue #0000CC mark with light blue #009CFF swoosh and blue wordmark) sits at the bottom left. No overlay or tint. Lighting is flat.
Slide 2
Introduction / Francesca DeMartino / Chief Investor Relations Officer, / Senior Vice President / Third Quarter 2026 Earnings / 2
Visuals: One photograph and one logo. Photograph: a circular-cropped head-and-shoulders portrait of a smiling woman with long, wavy, shoulder-length brown hair, wearing a bright royal-blue blazer and small gold drop earrings. She faces the camera slightly turned, with a white studio backdrop that fades into the blue slide. Lighting is soft, even and frontal. Dominant colours are white, royal blue and warm brown skin tones. The photo is circular, not full-bleed, and is ringed by a dotted light-violet circle of small dots about 1% of the slide width apart. Logo: the white Pfizer wordmark with its swirl mark at bottom-left, about 6% wide.
Slide 3
Forward-Looking Statements and Non-GAAP Financial Information
• Our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We include forward-looking statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; reorganizations; business plans, strategy, goals and prospects; expectations for our product pipeline (including products from completed or anticipated acquisitions), in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical development plans, discontinuations, clinical trial results and other developing data, revenue contribution and projections, pricing and reimbursement, market dynamics, including demand, market size and utilization rates and growth, performance, timing and duration of exclusivity and potential benefits; the impact and potential impact of tariffs and pricing dynamics; global economic and/or geopolitical instability, foreign exchange rate fluctuations and inflationary pressures; strategic reviews; leverage and capital allocation objectives; an enterprise-wide cost realignment program (including anticipated costs, savings and potential benefits); a manufacturing optimization program designed to reduce our cost of goods sold (including anticipated costs, savings and potential benefits); dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on growth opportunities and prospects; our voluntary agreements with the U.S. Government designed to lower drug costs for U.S. patients and to include certain Pfizer products on the TrumpRx.gov platform, and Pfizer’s plans to further invest in U.S. manufacturing and potential tariff impacts; manufacturing and product supply; our expectations regarding the impact of COVID-19 on our business, operations and financial results; our expectations regarding AI and our ability to successfully integrate and scale our AI initiatives; and other statements about our business, operations and financial results. Among other things, statements regarding revenue and earnings per share growth; anticipated operating and financial performance; cash flow outlook; the development or commercial potential of our product pipeline, in-line products, product candidates and additional indications or combinations, including expected clinical trial protocols, the timing and potential for the initiation and progress of clinical trials and data read-outs from trials, including our vaccine candidates such as our next generation pneumococcal conjugate vaccine candidates; the timing and potential for the submission of applications for and receipt of regulatory approvals; the timing and potential for product launches and commercialization; expected profile and labeling; potential revenue; expected breakthrough, best or first-in-class or blockbuster status or expected market entry of our medicines or vaccines; the regulatory landscape; and the competitive landscape are forward-looking and are estimates that are subject to change and subject to, among other risks, assumptions and uncertainties, clinical trial, regulatory and commercial success, demand, availability of supply, excess inventory write-offs, product recalls, withdrawals, competitive and market dynamics and recent changes, and potential changes to economic, trade and foreign policy in the U.S. and globally, including, without limitation, tariffs, trade restrictions, retaliatory trade measures or other changes in laws, regulations or policy regarding trade, potential changes to U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, including international reference pricing, including Most-Favored-Nation drug pricing, and changes to vaccine or other healthcare policy in the U.S. These statements may be affected by underlying assumptions that may prove inaccurate or incomplete, and are subject to risks, uncertainties and other factors that may cause actual results to differ materially from past results, future plans and projected future results. Additional information regarding these and other factors can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in Pfizer's subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.
• The discussions during this conference call will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles (GAAP). Additional information regarding non-U.S. GAAP financial measures can be found on slides 31-32 and in Pfizer's earnings release furnished with Pfizer’s Current Report on Form 8-K dated November 3, 2026. Any non-U.S. GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by U.S. GAAP, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies.
• Today’s discussions and presentation are intended for the investor community only; they are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. Definitive conclusions cannot be drawn from cross-trial comparisons or anticipated data as they may be confounded by various factors and should be interpreted with caution. All trademarks in this presentation are the property of their respective owners.
• Certain of the products and product candidates discussed during this conference call are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer’s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.
Third Quarter 2026 Earnings
3
Slide 4
Opening Remarks
Albert Bourla
Chairman and Chief Executive Officer
Third Quarter 2026 Earnings
4
Visuals: Photograph of a middle-aged man with short greying-brown hair and dark-rimmed rectangular glasses, wearing a light blue open-collar shirt, looking towards the camera with a slight closed-mouth smile; head and shoulders framing, subject centred in the circle; soft even studio lighting; neutral light-grey backdrop (about #D3D3D3); the photo is cropped to a circle and sits in a boxed circular frame with a ring of small lavender dots (about #8F8FF0) around its edge, the dots overlapping the blue background and not the photo. Pfizer logo (wordmark with stylised P-shaped mark) in white at bottom left.
Slide 5
2026 Strategic Priorities
Maximize value of key transactions
Deliver on critical R&D milestones
Invest to maximize post-2028 growth
Scale AI across our business
Pfizer
Third Quarter 2026 Earnings
5
Visuals: One target icon, a line illustration of a bullseye with an arrow. It has three concentric lavender (#A78BFA) rings, an arrow with a lavender shaft and a flag-shaped fletching pointing into the centre, and a dotted lavender outer circle. Two thick arc segments sit on the outer circle: a dark blue (#0000C9) arc on the left and a bright blue (#0A9CF0) arc on the right, each covering roughly a quarter of the circle. The icon is centred in the grey left column. No photographs, charts or tables. The Pfizer wordmark logo sits in the footer.
Slide 6
Maximize Value of Key Transactions
Q3'26
37%
op revenue growth from acquired products 1
Seagen
39%
YoY revenue growth in U.S. / for Seagen products
Metsera
10
berobenatide 2 pivotal / studies advancing in 2026; / VESPER-6 3 ~50% enrolled, / SOLIS-1 4 fully enrolled
Biohaven
33%
NURTEC YoY op revenue / growth
Third Quarter 2026 Earnings
1. See slides 31-32 for definitions; 2. Ultra-long-acting GLP-1 receptor agonist (PF'3944); 3. Phase 3 study of berobenatide for monthly chronic weight management (started June 2026); 4. Phase 2b study of berobenatide + PF'3945 and PF'3945 monotherapy for chronic weight management.
Op=operational; YoY=year-over-year
6
Visuals: Three circular icon badges, one above each card heading, each a white disc with a dotted lavender outline and a thick dark-blue arc on the left and a bright-blue arc on the right, with a teal line icon inside. Left card (Seagen): a teal line drawing of a virus-like cluster with small circles around it. Middle card (Metsera): a teal line drawing of a heart with an ECG pulse line running across it and a small dot at the right end. Right card (Biohaven): a teal line drawing of a head with both hands on the temples and small lightning-bolt marks above it. Icons use teal #1BB5A5-like strokes on white. The Pfizer logo at bottom-left is a blue wordmark with an abstract blue swoosh mark. No photographs or charts.
Slide 7
Deliver on Critical R&D Milestones
Disciplined progress with robust, diversified pipeline
2026 accomplishments to date1
16
Key Phase 3 study starts
7
Key data readouts
5
Key regulatory approvals
Since August 4, 2026:
8
Key Phase 3 study starts
1
Key data readout
2
Key regulatory approvals
Tilrekimig
Atopic dermatitis (x2); Asthma
Berobenatide
Weekly CWM (China); Weekly & Monthly CWM (Japan)
Nurtec ODT (rimegepant) orally disintegrating tablets 75 mg
Chronic migraine
Litfulo (ritlecitinib) capsules 50mg
Moderate alopecia areata
ELREXFIO (elranatamab-bcmm) injection for subcutaneous use 44 mg/1.1 mL 76 mg/1.9 mL
MagnetisMM-32
TUKYSA tucatinib 50 mg | 150 mg tablets
HER2CLIMB-05
TALZENNA talazoparib 0.5mg capsules + Xtandi (enzalutamide) 40 mg tablets | 80 mg tablets
TALAPRO-3
Pfizer
Third Quarter 2026 Earnings
CWM=Chronic weight management
1. Inclusive of select key pipeline milestones achieved in late 2025 including PADCEV EV-303 regulatory approval, Symbiotic-GI-03 study start and VESPER-4 study start.
7
Visuals: Three stat cards across the upper panel. Card 1 (dark blue #0000CA) shows the numeral 16 with label 'Key Phase 3 study starts', a white circle icon at top-right showing a flask with bubbles in blue line art, and a row of 14 white dashes along the bottom edge. Card 2 (bright blue #0095FF) shows 7 with label 'Key data readouts', a white circle icon with a document and line chart in blue, and 7 white dashes along the bottom. Card 3 (teal #00B7A5) shows 5 with label 'Key regulatory approvals', a white circle icon with a document and magnifying glass in teal, and 5 white dashes along the bottom. The dashes are about estimated, each a short white bar about 1.2% of slide height tall. Three chevron-shaped headers below: dark blue #0000CA chevron with '8 Key Phase 3 study starts', bright blue #0095FF chevron with '1 Key data readout', teal #00B7A5 chevron with '2 Key regulatory approvals'; chevrons point right with a notched left edge. Under the first chevron, four rows separated by thin grey rules: Tilrekimig (serif wordmark) with 'Atopic dermatitis (x2); Asthma'; Berobenatide (serif wordmark) with 'Weekly CWM (China); Weekly & Monthly CWM (Japan)'; Nurtec ODT (rimegepant) logo with 'Chronic migraine'; Litfulo (ritlecitinib) capsules 50mg logo with 'Moderate alopecia areata'. Under the second chevron, the ELREXFIO (elranatamab-bcmm) logo with a yellow and blue swoosh mark, labelled 'MagnetisMM-32'. Under the third chevron, two rows separated by a grey rule: the TUKYSA tucatinib logo (teal square mark, red and dark-teal lettering, 50 mg | 150 mg tablets) labelled 'HER2CLIMB-05', and the TALZENNA talazoparib 0.5mg capsules logo plus Xtandi (enzalutamide) 40 mg tablets logo (orange emblem, red lettering) joined by a plus sign, labelled 'TALAPRO-3'. Two thin vertical grey divider lines separate the three columns. Pfizer logo bottom-left in blue (#0000CA) with a swirl mark.
Slide 8
Invest to Maximize Post–2028 Growth
Driving growth toward end of the decade
Robust and accelerated approach to R&D
Successful commercial launch of new products
Bolt-on business development
Maintain dividend
Third Quarter 2026 Earnings
8
Visuals: Diagram. Shapes from back to front: (1) a soft grey drop-shadow image (1158 by 240 px) sitting under the top pill, offset downward; (2) one rounded pill (stadium) filled #0095FF, labelled 'Driving growth toward end of the decade' in white; (3) three vertical grey cylindrical connector bars (54 by 257 px images, shaded light grey with a soft gradient) at about x 29.7%, 48.6% and 67.8%, each running from the bottom edge of the pill down to the top edge of one box; (4) three white rounded rectangles with a #0095FF outline, labelled from left to right 'Robust and accelerated approach to R&D', 'Successful commercial launch of new products' and 'Bolt-on business development'; (5) one full-width rounded rectangle filled #0000C9, labelled 'Maintain dividend' in white. Arrows: none; the connectors are plain bars linking the pill to each box. Logo: Pfizer logo (blue wordmark with swoosh mark, about 119 by 49 px) at bottom-left. No photographs or charts.
Slide 9
Scale AI Across Our Business
Continued AI-powered efficiency improvement in Commercial, R&D and Manufacturing
Commercial
R&D
Manufacturing / Supply
R&D
• Accelerating R&D innovation
•
New pharmacovigilance platform harnesses advanced AI, intelligent automation
Third Quarter 2026 Earnings
9
Visuals: Three rounded grey cards in a vertical column, each with a white circular icon badge at left and a blue label at right: Commercial with a gear and upward arrows icon in lilac line art; R&D (outlined in blue, highlighted) with a microscope icon; Manufacturing / Supply with a factory and smoke-stack icon. Each badge is a white circle with a dotted lilac outer ring and a dark-blue to bright-blue arc accent on the left and right. A blue gradient wedge (from #0095FF at the R&D card edge fading to white at the detail panel) fans from the R&D card to the large panel. The large panel contains a larger circular badge with a microscope icon in lilac line art, the heading 'R&D' and two bullets. A soft grey drop shadow sits beneath the panel. Icon line art is lilac #A78BFA-like tone with dark blue (#0000C9) and bright blue (#0095FF) arc accents. Pfizer logo (blue wordmark with stylised blue swirl) at bottom left. No charts or tables.
Slide 10
Financial Review
Cecile Guegan
Chief Financial Officer,
Executive Vice President
Third Quarter 2026 Earnings
10
Visuals: One photograph: a head-and-shoulders portrait of a woman with grey hair pulled back into a low ponytail, wearing dark rectangular glasses and a dark top, looking straight at the camera with a neutral expression. It is cropped to a circle (525 by 525 px source) with a light, out-of-focus cream and white background, soft even front lighting and a tight centred framing that crops at the shoulders. The circle has a dotted lavender ring (about #8080FF, small dots, roughly 2% of slide width diameter spacing) concentric around it, not touching the photo edge. No overlay or tint on the photo. A small Pfizer wordmark logo with the blue-and-white emblem sits in the bottom left in white.
Slide 11
Q3 2026 Revenues and Adjusted¹ Diluted EPS
Revenues
Adjusted¹ Diluted EPS
$16.6B
$0.87
Focused execution drives strong performance
1. See slides 31-32 for definitions, including with respect to non-GAAP financial measures.
Third Quarter 2026 Earnings
11
Visuals: Two identical icon-in-circle graphics, one centred above each grey card. Each consists of a white circle backing with a dotted lilac ring and a thick arc on the left in dark blue #0000C9 and on the right in bright blue #0095FF, forming a broken outer ring. Left icon: a line-art browser window in bright blue #0095FF with three dots in the title bar, two short text lines on the left, and a bar chart with a magnifying glass over its upper right corner, drawn with rounded strokes of about 2% of slide height. Right icon: a line-art document with folded corner and two text lines above a table grid of rows and columns, in bright blue #0095FF with rounded strokes, overlapping a second page behind it. Pfizer logo at bottom left in dark blue #0000C9 and bright blue. No charts or photographs.
Slide 12
Quarterly Revenue and Non-GAAP Financial Highlights1 / $ in billions, except EPS / Q3 2026 / Q3 2025 / Op. / Change / Key Highlights / Revenue2 / $16.6B / $16.7B / — / Flat revenue growth YoY. Strong non-COVID revenue growth of 7% operationally, / more than offset by a decline in revenue from Paxlovid, Comirnaty, the Prevnar / family and several other products across categories / Adj.1 Cost of Sales / as a % of revenues / 23.2% / 23.9% / -0.7 ppts / Decrease primarily driven by a favorable change in sales mix, partially offset by the / non-recurrence of a favorable revision to our estimate of accrued royalties in Q3 / 2025 / Adj.1 SI&A Expenses / $3.2B / $3.2B / +2% / Increase primarily reflecting an increase in compensation-related expenses in the / quarter & a lower favorable adjustment of U.S. healthcare reform fees recorded in / Q3 2026 vs. Q3 2025, partially offset by a decrease in marketing & promotional / spend from more targeted investments & ongoing productivity improvements / Adj.1 R&D Expenses / $2.9B / $2.5B / +18% / Increase primarily driven by an anticipated net increase in spending in certain / oncology and obesity product candidates, as well as an increase in compensation- / related expenses in the quarter / Adj.1, 2, 3 Diluted EPS / $0.87 / $0.87 / -2% / Decrease primarily reflects higher total income taxes and R&D expenses, largely / offset by lower Acquired In-Process R&D expenses / 1. See slides 31-32 for definitions, including with respect to non-GAAP financial measures; 2. Unfavorable FX impact on Revenue of $15M (or 0%); favorable FX impact on Adj. Diluted EPS of $0.02 (or 2%); 3. Q3 2026 GAAP Diluted EPS of $0.56 (or -9% GAAP % change). / Third Quarter 2026 Earnings / 12
Visuals: Table with five columns and five body rows plus a header row. Header columns: $ in billions, except EPS (blank label column); Q3 2026; Q3 2025; Op. Change; Key Highlights. Row 1: Revenue2 | $16.6B | $16.7B | — | Flat revenue growth YoY. Strong non-COVID revenue growth of 7% operationally, more than offset by a decline in revenue from Paxlovid, Comirnaty, the Prevnar family and several other products across categories. Row 2: Adj.1 Cost of Sales as a % of revenues | 23.2% | 23.9% | -0.7 ppts | Decrease primarily driven by a favorable change in sales mix, partially offset by the non-recurrence of a favorable revision to our estimate of accrued royalties in Q3 2025. Row 3: Adj.1 SI&A Expenses | $3.2B | $3.2B | +2% | Increase primarily reflecting an increase in compensation-related expenses in the quarter and a lower favorable adjustment of U.S. healthcare reform fees recorded in Q3 2026 vs. Q3 2025, partially offset by a decrease in marketing and promotional spend from more targeted investments and ongoing productivity improvements. Row 4: Adj.1 R&D Expenses | $2.9B | $2.5B | +18% | Increase primarily driven by an anticipated net increase in spending in certain oncology and obesity product candidates, as well as an increase in compensation-related expenses in the quarter. Row 5: Adj.1, 2, 3 Diluted EPS | $0.87 | $0.87 | -2% | Decrease primarily reflects higher total income taxes and R&D expenses, largely offset by lower Acquired In-Process R&D expenses. The Q3 2026 column is filled light blue #BDE7FF, and the label column and body rows 1 to 5 alternate-free grey #F2F2F2 fills. No chart, photograph or illustration. The only logo is the Pfizer wordmark.
Slide 13
Strong Revenue Growth from Launched and Acquired Products 1
$ in Billions
$2.9
$3.8
32%
op YoY
Q3 2025
Q3 2026
Upcoming LOEs expected to be partially offset by
strong revenue growth from launched and acquired products
1. See slides 31-32 for definitions.
LOE=loss of exclusivity; op=operational; YoY=year-over-year
Third Quarter 2026 Earnings
13
Visuals: Chart: vertical column chart, no title beyond the slide title, subtitle '$ in Billions' (units in billions of US dollars). Two series-free categories on a shared baseline: Q3 2025 with labelled value $2.9 (bar fill dark blue #0000CC, top at about 39.6% of slide height, width about 20% of slide width, left edge about 19.5%); Q3 2026 with labelled value $3.8 (bar fill bright azure #0091FF, top at about 26.8% of slide height, width about 20%, left edge about 61.1%). Bars rest on a thin grey (#9A9A9A) horizontal baseline spanning about 8.8% to 91.9% of slide width at about 66.3% of slide height. No y-axis, no gridlines, no numeric axis scale and no legend are printed; the value labels are the only numbers. Highlighted element: a dotted purple (#9D73F7) circle about 20% of slide width in diameter, centred near x 50%, y 34%, with a dark blue arc on its upper-left and a light blue arc on its lower-right, containing the text 32% over op YoY. Two purple (#9D73F7) straight arrows with filled triangular heads point from the top-right of the Q3 2025 bar toward the badge and from the badge toward the top-left of the Q3 2026 bar. Full-bleed lighting is flat; no photographs, icons or shadows. The Pfizer logo is a small blue (#0000CC) wordmark with a stylised swoosh mark at bottom-left.
Slide 14
2026 Financial Guidance:
Raises 2026 Revenue Range and Adjusted Diluted EPS Range
Revenues
$62.0 to $64.0 Billion
(previously $60.5 to $62.5 billion)
Adjusted SI&A Expenses
$12.5 to $13.5 Billion
Adjusted R&D Expenses
$10.8 to $11.8 billion
(previously $10.5 to $11.5 billion)
Effective Tax Rate on Adjusted Income
~15.0%
Adjusted Diluted EPS
$2.95 to $3.05
(previously $2.80 to $3.00)
1. See slides 31-32 for definitions, including with respect to non-GAAP financial measures, and additional information regarding Pfizer's 2026 financial guidance. Current financial guidance does not anticipate any share repurchases in 2026.
Third Quarter 2026 Earnings
14
Visuals: Table with 5 rows and 2 columns, no header row. Column 1 (labels, left-aligned, bold black): Row 1 'Revenues'; Row 2 'Adjusted SI&A Expenses'; Row 3 'Adjusted R&D Expenses'; Row 4 'Effective Tax Rate on Adjusted Income'; Row 5 'Adjusted Diluted EPS'. Column 2 (values, centred, regular black, with italic grey-black parenthetical prior values beneath in rows 1, 3 and 5): Row 1 '$62.0 to $64.0 Billion' with '(previously $60.5 to $62.5 billion)'; Row 2 '$12.5 to $13.5 Billion' with no prior value; Row 3 '$10.8 to $11.8 billion' with '(previously $10.5 to $11.5 billion)'; Row 4 '~15.0%' with no prior value; Row 5 '$2.95 to $3.05' with '(previously $2.80 to $3.00)'. Row fills: label column cells filled #F2F2F2 in every row; value column cells white. Horizontal hairline rules in mid-grey (about #BFBFBF, about 0.1% of slide height) at the top, between rows and at the bottom of the table. No chart, photograph or icons. Small Pfizer logo at bottom left in blue.
Slide 15
YTD Q3 2026: Allocating Capital to Enhance Shareholder Value
Driving a balanced capital allocation strategy to reinvest in our business and return value to shareholders
Reinvest in Our Business
$9.2B
In internal¹ and external R&D²
Maintain and Grow Our Dividend
$7.3B
Returned to shareholders
De-lever Our Balance Sheet
~2.7x
Continue to maintain gross leverage target over time³
Share Repurchases⁴
None completed
to date in 2026
Disciplined and balanced capital allocation
between reinvestment and returning value to shareholders
Third Quarter 2026 Earnings
1. $8.3B in internal R&D; 2. ~$850M in business development transactions, primarily reflecting the Innovent Biologics, Inc. in-licensing deal; 3. Expect leverage to remain around current levels, or modestly higher, during the LOE transition period; 4. Current financial guidance does not anticipate any share repurchases in 2026.
15
Visuals: Four line icons, each inside its circle at the top of its card. (1) Purple #9D73F7 line icon of a lightbulb with a gear and radiating rays, representing reinvestment in the business. (2) Blue #0095FF line icon of an eye with an upward trend arrow inside the iris and dotted lines beneath, representing maintaining and growing the dividend. (3) Teal #0DBDBA line icon of a browser-style window containing a bar and line chart with a magnifier and a pointer, representing deleveraging the balance sheet. (4) Green #67BB6E line icon of a bar chart with a rising line and circular markers on a baseline with a dotted vertical axis, representing share repurchases. The four icons are drawn at the same scale with 2px-style outline strokes and no fill. No charts, photographs or illustrations otherwise. The Pfizer logo is a blue #0000C9 wordmark with a stylised blue mark at bottom left.
Slide 16
Key Takeaways and Expectations / Operational Excellence / Driving consistent execution / and strong portfolio performance / Financial Discipline / Driving productivity while / prioritizing investment in the pipeline / Managing upcoming losses of exclusivity while investing to support / a return to growth toward the end of the decade / Third Quarter 2026 Earnings / 16
Visuals: Two pairs of circular icon badges, one above each top panel heading. Each badge is a white circle (about 15% by 26% of the slide) framed by a dotted lilac circle outline with a thick arc on the left in dark navy (about #0000C9) and a thick arc on the right in bright blue (about #0095FF), leaving the top open. Left badge: a lilac line-icon of three ascending bar-chart columns (short, medium, tall) with a rising curved arrow above them pointing up-right and a circle with a checkmark overlapping the right end of the baseline. Right badge: a lilac line-icon of a balance scale with a central post and circular pivot, the left pan holding a stack of coins and the right pan holding a flask (Erlenmeyer) shape, on a rounded base. Both icons are lilac (about #A78BFA) line art with rounded stroke ends and no fill. No photographs, charts or tables. The Pfizer wordmark logo at bottom-left is a blue swoosh mark with the italic word 'Pfizer' in dark blue (about #0000C9).
Slide 17
Scientific Updates / Chris Boshoff MD, PhD / Chief Scientific Officer and President, / Research and Development / Third Quarter 2026 Earnings / 17
Visuals: One photograph: a head-and-shoulders portrait of a man with dark, wavy, tousled hair, a dark suit jacket, a white open-collared shirt, looking toward the viewer with a slight closed-mouth smile, face centred and framed from mid-chest up. The photo is placed as a 576 by 576 pixel image cropped to a circle, sitting on a flat light grey (#D3D3D3) disc, with the head filling most of the circle. Lighting is soft and even, with a neutral grey backdrop and natural skin tones. A ring of small evenly spaced lavender dots (about #9B8CFF, roughly 1% of slide width each) circles the portrait outside its edge, approximately 6.8% to 34.7% across and 28% to 77% down, as a decorative dotted border. The Pfizer logo (blue-and-white wordmark with the stylised mark and italic 'Pfizer' lettering) is white and sits bottom-left. No charts, tables or other graphics.
Slide 18
MM-32 Data Support Potential ELREXFIO Expansion in DCE MM
Positive Phase 3 supporting ELREXFIO fixed-dose monotherapy in post-CD38 DCE population
Statistically Significant and Clinically Meaningful PFS Benefit with ELREXFIO vs. Three SOC Regimens¹
Trial in Post-CD38 Double Class Exposed Multiple Myeloma
>75%
Progression-free with ELREXFIO treatment²
~68%
PFS rate at 18 months with ELREXFIO²
Manageable, potentially differentiated safety profile
ELREXFIO Treatment
Investigator's Choice¹
27.5%
Grade ≥3 infections
0.8%
Grade 5 infections
18.1%
Grade ≥3 infections
1.6%
Grade 5 infections
Plan to submit data to global health authorities
MM-5 and MM-32 Support ELREXFIO Monotherapy from First Relapse, Regardless of Prior CD38 Exposure
Ambition to Expand Eligible Patient Population ~5x Through Ongoing Pivotal Trials³⁻⁵
Third Quarter 2026 Earnings
18
1. Investigator's choice of Kd, PVd, or EloPd; 2. At time of the interim analysis; 3. Pfizer assumptions and Oracle incident and newly recurrent patients, 2026; 4. ELREXFIO is FDA approved under accelerated approval for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody; 5. Ongoing Phase 3 trials include MagnetisMM-5, MagnetisMM-32, MagnetisMM-6, MagnetisMM-7, and ElLen (Phase 3 trial led by the Intergroupe Francophone du Myélome); DCE=Double class exposed; EloPd= Elotuzumab, pomalidomide and dexamethasone; Kd=Carfilzomib and dexamethasone; MM=Multiple myeloma; MM-5=MagnetisMM-5 Phase 3 trial; MM-32=MagnetisMM-32 Phase 3 trial; PFS=Progression-free survival; PVd=Pomalidomide, bortezomib and dexamethasone; SOC=Standard of care
Visuals: Left panel: a navy header bar with two-line white bold heading, below which a line of text and two large statistics separated by a thin vertical grey divider line at about x 26.7%, y 41% to 58%. Statistic 1 is '>75%' with its caption 'Progression-free with ELREXFIO treatment'. Statistic 2 is '~68%' with its caption 'PFS rate at 18 months with ELREXFIO'. Right panel: a bold black heading above two navy-headed boxes. Box 1 'ELREXFIO Treatment' lists '27.5%' Grade ≥3 infections and '0.8%' Grade 5 infections. Box 2 'Investigator's Choice' lists '18.1%' Grade ≥3 infections and '1.6%' Grade 5 infections. No chart or table. Bracket line: a thin black horizontal line with small upturned end ticks at both ends, spanning x 2.4% to 97.6% at y 66.8%, interrupted by a white box behind the caption 'Plan to submit data to global health authorities'. Banner: a pale light-blue-to-white gradient rectangle with a faint translucent photographic texture, bordered by a thin light-grey outline, with two centred bold black lines of text. Pfizer logo: the blue Pfizer wordmark with its stylised blue mark at bottom left.
Slide 19
Atirmociclib: Aiming to Expand Pfizer’s Breast Cancer Leadership / Atirmociclib is a CDK4 inhibitor and potential new cell-cycle therapy backbone for HR+ breast cancer / HR+ / HER2- Breast Cancer Portfolio / (~70% of U.S. breast cancer cases are HR+ / HER2-)1 / U.S. Patients2 / ~200K3 / ~35K / ~25K+ / eBC / mBC 1L / mBC 2L / Atirmociclib’s High CDK4 vs. CDK6 Selectivity May Provide an Improved Profile vs. CDK4/6 Inhibitors / Atirmociclib Strategy / Increase CDK4 Inhibition / Improve Tolerability / Maximize Efficacy / Decrease CDK6 Inhibition / CDK4 Selectivity (CDK4:CDK6)5 / Palbociclib / Ribociclib / Abemaciclib / Atirmociclib / 1.5-fold / 4-fold / 14-fold / 33-fold / Not intended to compare efficacy or safety across these molecules / Approved / Late-Stage Pipeline4 / Atirmociclib / Atirmociclib / Prifetrastat / Third Quarter 2026 Earnings / 1. National Cancer Institute Surveillance, Epidemiology, and End Results Program, Accessed October 24, 2026; 2. Oracle incident and newly recurrent U.S. patients, 2026; 3. Includes patients under the standard (neo)adjuvant definition; 4. Investigational programs in Phase 3 or with a Phase 3 start anticipated in 2H 2026 / 1H 2027; 5. Palmer et al. Cancer Cell. 2025 Mar 10;43(3):464-481.e14; 1L=First-line; 2L=Second-line; CDK4=Cyclin-dependent kinase 4; CDK4/6=Cyclin-dependent kinase 4/6; CDK6=Cyclin-dependent kinase 6; eBC=Early breast cancer; HER2=Human epidermal growth factor receptor 2; HR=Hormone receptor; mBC=Metastatic breast cancer / 19
Visuals: Left panel: three blue (#0095FF) rounded pills labelled eBC, mBC 1L and mBC 2L, each with a large patient count above (~200K3, ~35K, ~25K+). A faint pale-blue (#CCEAFF at 50% opacity) silhouette of the continental United States sits behind the U.S. Patients heading. In the Approved row, the IBRANCE palbociclib logo (purple wordmark with green swoosh) appears under mBC 1L and under mBC 2L; eBC has none. In the Late-Stage Pipeline row, blue (#0095FF) bold text reads Atirmociclib under eBC, Atirmociclib under mBC 1L, and Prifetrastat under mBC 2L. Right panel: a strategy diagram with a light-blue gradient up arrow under 'Increase CDK4 Inhibition' with 'Maximize Efficacy' below it, a pale-blue plus sign between the two sides, and a light-blue gradient down arrow under 'Improve Tolerability' with 'Decrease CDK6 Inhibition' below it. The table has a blue header bar and four columns: Palbociclib 1.5-fold, Ribociclib 4-fold, Abemaciclib 14-fold, and Atirmociclib 33-fold (highlighted in lavender #D5D5FF with bold text, its header cell in #0000C9). No chart axes or legend. The Pfizer logo (blue wordmark) sits bottom left.
Slide 20
Building Momentum for Atirmociclib in HR+ Breast Cancer
ESMO 2026: Ph 2 FOURLIGHT-1 Study in 2L mBC
1
Atirmo Regimen Reduced Risk of Disease Progression or Death by 40%
ASCO 2026: Ph 2 FOURLIGHT-2 Study in eBC
2
Atirmo Drives Strong Anti-Proliferative Effects
92% Initiated Atirmociclib Within Three Months of Discontinuing CDK4/6i
PFS Probability (%)
100
90
80
70
60
50
40
30
20
10
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
82.5%
62.3%
44.8%
68.9%
51.9%
22.5%
Atirmociclib + Fulvestrant
ICT*
Hazard Ratio: 0.60
95% CI: 0.440, 0.825, p=0.0007
Time (Months)
Proportion of Complete Cell Cycle Arrest (%)
88%
(45/51)
18%
(10/56)
Atirmociclib + Letrozole
Letrozole
Data in CDK4/6i-Experienced Patients Provide Further Confidence for
Ongoing Ph 3 Trial in First-Line Population
Data Support
Planned Ph 3 Start in Early Breast Cancer
in Combination with Giredestrant
3
*Investigator’s choice of fulvestrant or everolimus + exemestane; 1. Giordano et al. 2026 European Society for Medical Oncology Congress, Presentation 1842O; 2. Goel et al. 2026 American Society of Clinical Oncology Annual Meeting (Abstract 518), data are at day 14, error bars represent 95% confidence intervals; 3. For more information see clinicaltrials.gov NCT07890597. Giredestrant is an investigational oral selective oestrogen receptor degrader under development by Roche; 2L=Second-line; ASCO=American Society of Clinical Oncology Annual Meeting; Atirmo=Atirmociclib; CDK4/6i=Cyclin-dependent kinase 4/6 inhibitor; CI=Confidence interval; ESMO=European Society for Medical Oncology Annual Congress; eBC=Early breast cancer; HER2=Human epidermal growth factor receptor 2; HR=Hormone receptor; ICT=Investigator’s choice of therapy; mBC=Metastatic breast cancer; Ph=Phase; PFS=Progression-free survival
Third Quarter 2026 Earnings
20
Visuals: Two charts. (1) Left: Kaplan-Meier progression-free survival curve, untitled inside the panel, with a headline text box. Y axis labelled 'PFS Probability (%)', range 0 to 100 in steps of 10. X axis labelled 'Time (Months)', range 0 to 20 in steps of 1. Series 1, 'Atirmociclib + Fulvestrant', dark navy line (about #244E75) with step drops and cross censoring marks; labelled values 82.5% at about 3 months, 62.3% at about 6 months, 44.8% at about 12 months; it ends near 29% at about 19 months. Series 2, 'ICT*', gold line (#D9A839) with censoring marks; labelled values 68.9% at about 3 months, 51.9% at about 6 months, 22.5% at about 12 months; it ends near 16% at about 17.5 months. Dotted vertical reference lines drop from the curves at 3, 6 and 12 months. Series labels sit on the right side of the plot ('Atirmociclib + Fulvestrant' in navy, 'ICT*' in gold). Hazard Ratio: 0.60 and 95% CI: 0.440, 0.825, p=0.0007 are printed in the lower-left of the plot area. No legend beyond the direct labels. (2) Right: vertical bar chart titled 'Proportion of Complete Cell Cycle Arrest (%)', no axis lines or scale shown. Bar 1, labelled 'Atirmociclib + Letrozole', bright blue #0095FF, value 88% (45/51), with a black error bar centred on the top of the bar, roughly from about 80% to 95%. Bar 2, labelled 'Letrozole', mid grey #7F7F7F, value 18% (10/56), with a black error bar roughly from about 12% to 25%. Bars sit on a thin light grey baseline. Values are printed above each bar, percentages bold and fractions regular. Highlighted points: none. Also a Pfizer logo (blue wordmark with swoosh) in the bottom-left corner.
Slide 21
Atirmociclib: Potential for Differentiated Safety & Target Coverage
High selectivity for CDK4 vs. CDK6 may improve safety / tolerability
Cross Trial Comparison: / FOURLIGHT-1 vs. Pivotal / Studies of Approved / CDK4/6 Inhibitors + / Fulvestrant in Advanced / Breast Cancer
Potential for Improved Safety / Tolerability with Atirmociclib
100
80
60
40
Participants, %
20
*
0
43
36 32
14
Neutropenia
Grade ≥3
Diarrhea / Any Grade
Dose reductions / due to AEs
KEY
Atirmociclib (FOURLIGHT-1, n=125)1
Palbociclib (PALOMA-3, n=345)2
Ribociclib (MONALEESA-3, n=483)3,4
Abemaciclib (MONARCH 2, n=441)5,6
Data represent a cross-trial comparison and are not from a head-to-head study. Definitive conclusions cannot be drawn from results across different clinical trials.
Third Quarter 2026 Earnings
21
*No grade 4/5 neutropenia reported; 1. Giordano et al. 2026 European Society for Medical Oncology Congress, Presentation 1842O, data represent treatment-emergent adverse events. n represents number of participants in atirmociclib + fulvestrant group; 2. IBRANCE prescribing information Section 6.1, Table 6. (Adverse Reactions (≥10%) in PALOMA-3) and percentage of patients with dose reductions due to an adverse reaction (n represents number of participants in palbociclib + fulvestrant group); 3. Neutropenia Grade ≥3 and diarrhea rates as reported in Slamon et al. J Clin Oncol. 2018 Aug 20;36(24):2465-2472. (n represents number of participants in ribociclib + fulvestrant group); 4. Dose reductions due to adverse reactions as reported in KISQALI prescribing information; 5. Neutropenia Grade ≥3 and diarrhea rates as reported in Sledge et al. J Clin Oncol. 2017 Sep 1;35(25):2875-2884 (n represents number of participants in abemaciclib + fulvestrant group); 6. Dose reductions due to adverse reactions as reported in VERZENIO prescribing information; AE=Adverse event; CDK=Cyclin-dependent kinase. Third-party trademarks are the property of their respective owners and any references are for identification purposes only.
Visuals: Bar chart (vertical, clustered). Title: 'Potential for Improved Safety / Tolerability with Atirmociclib', bold black, centred above the plot. Y-axis: 'Participants, %', linear, range 0 to 100, ticks every 20 (0, 20, 40, 60, 80, 100), axis line black thin. X-axis: three category groups with labels 'Neutropenia / Grade ≥3', 'Diarrhea / Any Grade', 'Dose reductions / due to AEs'. Series in each group, left to right: Atirmociclib (blue #0095FF), Palbociclib (lavender #AEAEFF), Ribociclib (light grey #BFBFBF), Abemaciclib (dark grey #595959). Printed values: Dose reductions group: Atirmociclib 14, Palbociclib 36, Ribociclib 32, Abemaciclib 43; an asterisk above the Neutropenia Atirmociclib bar, with footnote '*No grade 4/5 neutropenia reported'. Unprinted values, read by eye and therefore approximate: Neutropenia Grade ≥3 about 20 (Atirmociclib), about 65 (Palbociclib), about 52 (Ribociclib), about 25 (Abemaciclib); Diarrhea Any Grade about 27 (Atirmociclib), about 23 (Palbociclib), about 28 (Ribociclib), about 85 (Abemaciclib). No bars are highlighted beyond the asterisk. Legend: boxed key at bottom of chart with a dark vertical 'KEY' tab on the left, four entries in two columns: blue square 'Atirmociclib (FOURLIGHT-1, n=125)1'; lavender square 'Palbociclib (PALOMA-3, n=345)2'; light grey square 'Ribociclib (MONALEESA-3, n=483)3,4'; dark grey square 'Abemaciclib (MONARCH 2, n=441)5,6'. Navy arrow panel contains no chart; it is a text block. Pfizer logo at bottom left.
Slide 22
Tivunatamig: Potentially Transformative Next-Gen Backbone Therapy
Tivunatamig is a structurally differentiated PD-1 x VEGF bispecific antibody
Symbiotic Program: 2026 Ongoing and Planned Studies*
Phase 1**
Phase 2***
Phase 3
NSCLC: ADC Combos
1L Extensive Stage SCLC
1L mCRC
1L Renal Cell Carcinoma
1L Gastroesophageal Cancer
1L NSCLC (Sq + Nsq)
1L Transformed SCLC
1L Endometrial Cancer
Early Stage NSCLC
1L mUC (PADCEV‡ Combo)
Hepatocellular Carcinoma
1L mUC (±PADCEV‡)
Legend
Phase 1 Ongoing
Phase 2 Ongoing
Phase 3 Ongoing
Phase 3 Planned for 2026
Advanced in phase since 2Q earnings†
Symbiotic / Pfizer Clinical Trials
10
Ongoing clinical studies
8
Tumor types in 2026#
>225K1
Combined U.S. patient population targeted by 2026 Phase 3 studies
Third Quarter 2026 Earnings
22
*Potentially not exhaustive; **Includes Phase 1/2 studies in Phase 1 portion; ***Includes Phase 1/2 and Phase 2/3 studies in Phase 2 portion; ‡Pfizer and Astellas have a collaboration agreement to co-develop PADCEV; †Includes trials that were previously in an earlier phase progressing to the next phase and trials that have started since the 2Q 2026 earnings call; #Including studies that are ongoing or planned to begin in 2026; 1. Oracle patient metrics Stage IV incident and newly recurrent patients, updated Jan 2026; 1L=First-line; ADC=Antibody-drug conjugate; Gen=Generation; mCRC=Metastatic colorectal cancer; mUC=Metastatic urothelial cancer; NSCLC=Non-small cell lung cancer; Nsq=Non-squamous; PD-1=Programmed death receptor-1; SCLC=Small cell lung cancer; Sq=Squamous; VEGF=Vascular endothelial growth factor. Tivunatamig also known as PF'4404, SSGJ-707.
Visuals: Diagram-style grid of colour-coded rounded rectangles (no chart or table). Phase 1 column (teal #00897C): NSCLC: ADC Combos; 1L Renal Cell Carcinoma. Phase 2 column (bright blue #0095FF), with small white right-pointing triangles marking advanced items: 1L Extensive Stage SCLC; 1L Gastroesophageal Cancer; 1L Transformed SCLC; Early Stage NSCLC (triangle); Hepatocellular Carcinoma (triangle); 1L mUC (±PADCEV‡) (triangle). Phase 3 column: navy #000067 boxes 1L mCRC and 1L NSCLC (Sq + Nsq); lavender #C1C1FF boxes 1L Endometrial Cancer and 1L mUC (PADCEV‡ Combo). Legend box with black outline contains teal Phase 1 Ongoing, blue Phase 2 Ongoing, navy Phase 3 Ongoing, lavender Phase 3 Planned for 2026, and a black triangle with 'Advanced in phase since 2Q earnings†'. Right panel: Symbiotic Pfizer Clinical Trials logo (white wordmark with a circular swirl icon); stats 10, 8 and >225K1 with captions. Pfizer logo (blue swirl and wordmark) at bottom-left. Two thin white horizontal rules divide the stats panel.
Slide 23
Tivunatamig: Improved Response Rates in 1L NSCLC Study
cORR with Tivunatamig Exceeds SOC* in Phase 2 Study
Phase 2 Data at ESMO: Tivunatamig at Selected Pivotal Dose + Chemo vs.
Tislelizumab (China Approved PD-1) + Chemo in 1L All-Comers NSCLC¹
Non-squamous
Squamous
100%
80%
60%
40%
20%
0%
cORR
77.5%
80.7%
67.7%
44.7%
Top sections = increases
in cORR from SITC 2025²
Tivunatamig +
Chemo³ (n=40)
Tislelizumab +
Chemo³ (n=38)
Tivunatamig +
Chemo⁴ (n=57)⁵
Tislelizumab +
Chemo⁴ (n=31)
*SOC in China, where study was conducted
Median PFS Benchmarking for PD-1 x
VEGF Bispecifics + Chemo in 1L NSCLC
Phase 2: Tivunatamig + Chemo¹
Non-squamous
Squamous⁵
13.8 months
vs. 9.7 mo with PD-1 + chemo³
13.6 months
vs. 8.3 mo with PD-1 + chemo⁴
Phase 3 Benchmark: Ivonescimab + Chemo
Non-squamous
Squamous⁶
N/A
11.1 months
vs. 6.9 mo with PD-1 + chemo⁴
No head-to-head studies have been conducted between tivunatamig
and ivonescimab. Definitive conclusions cannot be drawn from results
across different clinical trials.
Improved cORRs from SITC 2025 to ESMO 2026 Provide Confidence to Expand & Accelerate Development
Third Quarter 2026 Earnings
23
1. Wu et al. 2026 European Society for Medical Oncology Congress (Abstract 2660P), study is conducted by 3SBio in China (selected pivotal dose for tivunatamig is 10 mg/kg Q3W). Error bars represent 95% confidence intervals; 2. Wu et al. 2025 Society for Immunotherapy of Cancer Annual Meeting (Abstract #1328); 3. Chemo combo partners were carboplatin and pemetrexed; 4. Chemo combo partners were carboplatin and paclitaxel; 5. Includes results from patients in both Cohort A and Cohort B of Part 2 of the study who received tivunatamig 10 mg/kg + carboplatin + paclitaxel (data from patients receiving tivunatamig in combination with carboplatin and nab-paclitaxel not shown); 6. HARMONi-6. Chen et al. Lancet. 2025 Nov 1;406(10515):2078-2088 (study evaluated squamous NSCLC only); 1L=First-line; cORR=Confirmed objective response rate; ESMO=European Society for Medical Oncology Annual Congress; Mo=Month; NSCLC=Non-small cell lung cancer; PD-1=Programmed death receptor-1; PFS=Progression-free survival; Q3W=Every three weeks; SITC=Society for Immunotherapy of Cancer Annual Meeting; SOC=Standard of care; VEGF=Vascular endothelial growth factor
Visuals: Chart: vertical stacked-bar chart titled 'cORR with Tivunatamig Exceeds SOC* in Phase 2 Study' (header bar) with subtitle 'Phase 2 Data at ESMO: Tivunatamig at Selected Pivotal Dose + Chemo vs. Tislelizumab (China Approved PD-1) + Chemo in 1L All-Comers NSCLC'. Y-axis titled 'cORR', unit percent, range 0% to 100%, ticks every 20%. X-axis split into two groups with headings 'Non-squamous' and 'Squamous', each with a horizontal rule above. Non-squamous: Tivunatamig + Chemo³ (n=40) bar with labelled total 77.5% (light blue #99D5FF lower segment about 0% to 57%, blue #0095FF upper segment about 57% to 77.5%); Tislelizumab + Chemo³ (n=38) bar labelled 44.7% (grey #BFBFBF lower segment about 0% to 37%, dark grey #7F7F7F upper segment about 37% to 44.7%). Squamous: Tivunatamig + Chemo⁴ (n=57)⁵ bar labelled 80.7% (light blue lower segment about 0% to 59%, blue upper segment about 59% to 80.7%); Tislelizumab + Chemo⁴ (n=31) bar labelled 67.7% (grey lower segment about 0% to 46%, dark grey upper segment about 46% to 67.7%). Error bars are black vertical lines with horizontal caps: approximately 61% to 89% for tivunatamig non-squamous, 28% to 61% for tislelizumab non-squamous, 67% to 90% for tivunatamig squamous, 49% to 83% for tislelizumab squamous. Highlighted: a light grey speech-bubble callout 'Top sections = increases in cORR from SITC 2025²' with its tail pointing to the blue segment of the Tivunatamig non-squamous bar. No legend. Right panel: three-column-style stat blocks with vertical and horizontal navy-grey divider lines; no photographs, icons or logos other than the Pfizer logo in the footer.
Slide 24
Ph 2 Atopic Dermatitis Data Provide Proof-of-Concept for Tilrekimig1
Tilrekimig is a potential first-in-class trispecific antibody targeting IL-4, IL-13 and TSLP
~50% Placebo-Adjusted EASI-75 Rate2
Efficacy potentially superior to dupilumab3*
Favorable Safety Profile
Low frequency of conjunctivitis and injection site reactions4
Pipeline-in-a-Product Opportunity
Strong data in atopic dermatitis support development in other type 2 inflammatory disorders
Tilrekimig Targets Pathways that are Validated by Approved Therapies Across Nine Different Diseases5
Late-Stage Studies in Atopic Dermatitis (Phase 3), Asthma (Phase 3) and COPD (Phase 2/3) are Ongoing
*Based on a cross-trial comparison6, not data from a head-to-head study. Definitive conclusions cannot be drawn from results across different clinical trials.
Third Quarter 2026 Earnings
24
1. Simpson et al. European Academy of Dermatology and Venereology Congress 2026 (AS-1730); 2. Achieved at Week 16 in two top Q4W dose groups (400 mg and 200 mg Q4W) in Stage 2 of trial. 400 mg dose group achieved placebo-adjusted EASI-75 rate of 49.4%, 200 mg dose group achieved placebo-adjusted EASI-75 response rate of 51.9%; 3. Ongoing Phase 3 trial includes a head-to-head evaluation of tilrekimig vs. dupilumab; 4. In doses up to 400 mg of tilrekimig Q4W, the observed frequency of conjunctivitis and injection site reactions in the Phase 2 study were lower than rates reported with IL-4 receptor alpha inhibitors and comparable to placebo; 5. Refers to FDA approved therapies targeting IL-4Rα (dupilumab), IL-13 (tralokinumab, lebrikizumab), and TSLP (tezepelumab); 6. Dupilumab Phase 3 data reported in Simpson et al. N Engl J Med 2016;375:2335-2348; COPD=Chronic obstructive pulmonary disease; EASI-75: ≥75% reduction in the Eczema Area and Severity Index; Ph=Phase; Q4W=Every four weeks
Visuals: Three white rounded rectangles with 2-3 pt navy #000067 outlines and a soft grey drop shadow, each about 29% wide and 36% tall, arranged left to right with equal gaps and each containing a light blue headline and dark navy body text. A full-width navy #000067 horizontal band runs behind the middle of the three cards. Below the middle card a light grey (#D9D9D9 fading to white) trapezoidal wedge tapers from the bottom edge of the middle card down to the top edge of the navy banner. A navy #000067 rounded rectangle banner with white bold headline and white regular subline sits beneath the cards. A blue Pfizer wordmark logo sits bottom-left. Superscript reference numbers are shown after text. No photographs or charts.
Slide 25
Aim to Deliver Best-in-Class, Next-Gen PCVs Designed for Leading / Serotype and Invasive Disease Coverage at Potential Launches / PCV25 Candidate for Pediatrics: Strong Phase 2 Data1 Support Ongoing Phase 3 / All 20 shared PREVNAR 20 / serotypes met 2-fold NI criterion* / for post-dose 4 (PD4) IgG GMR / Modeling predicts ≥22 / 25 serotypes will / meet more stringent 1.5-fold NI criterion* / for PD4 IgG GMR in a large Phase 3 trial2 / Totality of Ph 2 data support / ambition for coverage of / ~84% of U.S. pediatric IPD3 / Adults: Phase 1 Start for PCV35 Candidate Expected by Year-End 2026 / *2-fold and 1.5-fold non-inferiority criteria defined as the lower-bound of the 95% confidence interval of the GMR >0.5 and >0.667, respectively / Building on PREVNAR Platform’s Established Effectiveness, Safety, and / >25-Year Legacy of Helping to Protect Against Pneumococcal Disease / Third Quarter 2026 Earnings / 25 / 1. Smith et al. Immunogenicity of a 25-Valent PCV Compared with PCV20 in Healthy Infants: Evaluating a Candidate to Improve Pneumococcal Coverage in a Phase 2 Trial, Presented at / IDWeek 2026; 2. Actual clinical trial results may differ from expectations based on modeling; 3. For U.S. children <5 years old. Source - Centers for Disease Control and Prevention. Surveillance Reports, 2020-2024. Active Bacterial Core surveillance (ABCs). Accessed October 12, 2026. / https://www.cdc.gov/abcs/reports/index.html. Includes potential for / coverage of serotypes 6C and 15C with PCV25 based on cross-reactivity with 6A and 15B; Gen=Generation; GMR=Geometric mean ratio; IPD=Invasive pneumococcal disease; / NI=Non-inferiority; PCV=Pneumococcal conjugate vaccine; Ph=Phase
Visuals: 1. Photo/illustration: an abstract, low-contrast illustration of pale blue and lavender faceted, crystalline geometric shapes fills the central panel (1440 by 344 pixel image, same box as the panel). It is full-bleed within the panel and covered by a 60% opacity white tint, which washes it to a pale blue-white. Composition is wide and horizontal, uncropped, with soft diffuse lighting and no people or objects. 2. Shape: a navy (#000067) outline rectangle frames the central panel, about 0.3% of slide height stroke width, square corners. 3. Shape: a light grey (#F2F2F2) horizontal band sits at the bottom of the panel and holds the Adults line. 4. Shape: a solid navy (#000067) rounded rectangle, small corner radius, holds the two-line banner text. 5. Line: two thin vertical grey (about #B0B0B0) rules, about 0.1% of slide width, at about x 36% and x 71%, running from about y 37% to y 52%, separating the three columns. 6. Logo: the Pfizer logo at bottom left (about 5.9% wide by 4.4% high) in blue (#0000C9), a stylised swoosh mark followed by the lowercase wordmark 'Pfizer' in italic bold. No other visuals; no charts or tables.
Slides 26 to 32 continue in the full text file.
Download this deck
The hosted PDF of every library deck is free for readers of the SlideDeck Co newsletter. Join with your email and the viewer and download appear here.
Preparing a results presentation or business update of your own? The SlideDeck Co Standard Deck is a slide library for business reviews, updates and plans.






